Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

242 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Modernizing the assessment and reporting of adverse events in oncology clinical trials using complementary statistical approaches: a case study of the MOTIVATE trial.
Morisseau M, Gomez-Roca C, Viala M, Rabeau A, Loirat D, Munsch N, Thomas K, Pages C, Korakis I, Sibaud V, Delord JP, Filleron T, Cabarrou B. Morisseau M, et al. Among authors: delord jp. Invest New Drugs. 2024 Dec;42(6):664-674. doi: 10.1007/s10637-024-01481-9. Epub 2024 Nov 4. Invest New Drugs. 2024. PMID: 39495388
Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors.
Hiret S, Isambert N, Gomez-Roca C, Bennouna J, Sassi M, de Mont-Serrat H, Fan J, Schnell D, Delord JP. Hiret S, et al. Among authors: delord jp. Invest New Drugs. 2018 Dec;36(6):1044-1059. doi: 10.1007/s10637-018-0601-1. Epub 2018 May 29. Invest New Drugs. 2018. PMID: 29808308 Clinical Trial.
Emerging new anticancer therapies in 2013.
Gomez-Roca C, Delord JP. Gomez-Roca C, et al. Among authors: delord jp. Curr Opin Oncol. 2014 May;26(3):357-62. doi: 10.1097/CCO.0000000000000081. Curr Opin Oncol. 2014. PMID: 24709976 Review.
Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer.
Leary A, Le Tourneau C, Varga A, Sablin MP, Gomez-Roca C, Guilbaud N, Petain A, Pavlyuk M, Delord JP. Leary A, et al. Among authors: delord jp. Invest New Drugs. 2019 Aug;37(4):693-701. doi: 10.1007/s10637-018-0688-4. Epub 2018 Dec 14. Invest New Drugs. 2019. PMID: 30547316 Free PMC article. Clinical Trial.
[Subgroup analysis and forest plots: Limitations and interests].
Filleron T, Gilhodes J, Delord JP, Cabarrou B. Filleron T, et al. Among authors: delord jp. Bull Cancer. 2017 Jan;104(1):92-100. doi: 10.1016/j.bulcan.2016.09.023. Epub 2016 Nov 4. Bull Cancer. 2017. PMID: 27823809 Review. French.
242 results